Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment…
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative…
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated…
Into the Tropics: Introducing Breck Brew's New Juicy Oasis Fruited Hazy IPA The newly released Juicy Oasis uses real agave…
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing…
Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics,…
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager,…
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical DevelopmentCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN,…
Figure 1 Atacicept 72-week Data From the Phase 2b ORIGIN Trial Are Consistent With a Profile of True Disease Modification…
TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage…